BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25381339)

  • 1. 18F-FAZA PET imaging response tracks the reoxygenation of tumors in mice upon treatment with the mitochondrial complex I inhibitor BAY 87-2243.
    Chang E; Liu H; Unterschemmann K; Ellinghaus P; Liu S; Gekeler V; Cheng Z; Berndorff D; Gambhir SS
    Clin Cancer Res; 2015 Jan; 21(2):335-46. PubMed ID: 25381339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
    Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
    Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I.
    Ellinghaus P; Heisler I; Unterschemmann K; Haerter M; Beck H; Greschat S; Ehrmann A; Summer H; Flamme I; Oehme F; Thierauch K; Michels M; Hess-Stumpp H; Ziegelbauer K
    Cancer Med; 2013 Oct; 2(5):611-24. PubMed ID: 24403227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model.
    Cheng Z; Wei R; Wu C; Qing H; Jiang X; Lu H; Chen S; Li X; Xu G; Ai H
    Nucl Med Commun; 2015 Sep; 36(9):914-21. PubMed ID: 25973694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [
    Gammon ST; Pisaneschi F; Bandi ML; Smith MG; Sun Y; Rao Y; Muller F; Wong F; De Groot J; Ackroyd J; Mawlawi O; Davies MA; Gopal YNV; Di Francesco ME; Marszalek JR; Dewhirst M; Piwnica-Worms D
    Cells; 2019 Nov; 8(12):. PubMed ID: 31766580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18FDG, [18F]FLT, [18F]FAZA, and 11C-methionine are suitable tracers for the diagnosis and in vivo follow-up of the efficacy of chemotherapy by miniPET in both multidrug resistant and sensitive human gynecologic tumor xenografts.
    Trencsényi G; Márián T; Lajtos I; Krasznai Z; Balkay L; Emri M; Mikecz P; Goda K; Szalóki G; Juhász I; Németh E; Miklovicz T; Szabó G; Krasznai ZT
    Biomed Res Int; 2014; 2014():787365. PubMed ID: 25309926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients.
    Bollineni VR; Kerner GS; Pruim J; Steenbakkers RJ; Wiegman EM; Koole MJ; de Groot EH; Willemsen AT; Luurtsema G; Widder J; Groen HJ; Langendijk JA
    J Nucl Med; 2013 Aug; 54(8):1175-80. PubMed ID: 23753185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models.
    Kukuk D; Reischl G; Raguin O; Wiehr S; Judenhofer MS; Calaminus C; Honndorf VS; Quintanilla-Martinez L; Schönberger T; Duchamp O; Machulla HJ; Pichler BJ
    J Nucl Med; 2011 Oct; 52(10):1654-63. PubMed ID: 21859811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant [
    Kepes Z; Hegedus E; Sass T; Csikos C; Szabo JP; Szugyiczki V; Hajdu I; Kertesz I; Opposits G; Imrek J; Balkay L; Kalman FK; Trencsenyi G
    In Vivo; 2024; 38(2):574-586. PubMed ID: 38418132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
    Nielsen CH; Jensen MM; Kristensen LK; Dahlman A; Fröhlich C; Jacobsen HJ; Poulsen TT; Lantto J; Horak ID; Kragh M; Kjaer A
    Oncotarget; 2015 Nov; 6(35):37486-99. PubMed ID: 26460961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice.
    Jensen MM; Erichsen KD; Björkling F; Madsen J; Jensen PB; Højgaard L; Sehested M; Kjær A
    PLoS One; 2010 Sep; 5(9):e12965. PubMed ID: 20885974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.
    Moroz MA; Kochetkov T; Cai S; Wu J; Shamis M; Nair J; de Stanchina E; Serganova I; Schwartz GK; Banerjee D; Bertino JR; Blasberg RG
    Clin Cancer Res; 2011 Mar; 17(5):1099-110. PubMed ID: 21245090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant impact of different oxygen breathing conditions on noninvasive in vivo tumor-hypoxia imaging using [¹⁸F]-fluoro-azomycinarabino-furanoside ([¹⁸F]FAZA).
    Maier FC; Kneilling M; Reischl G; Cay F; Bukala D; Schmid A; Judenhofer MS; Röcken M; Machulla HJ; Pichler BJ
    Radiat Oncol; 2011 Nov; 6():165. PubMed ID: 22118419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia imaging with
    Melsens E; De Vlieghere E; Descamps B; Vanhove C; Kersemans K; De Vos F; Goethals I; Brans B; De Wever O; Ceelen W; Pattyn P
    Radiat Oncol; 2018 Mar; 13(1):39. PubMed ID: 29514673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside.
    Piert M; Machulla HJ; Picchio M; Reischl G; Ziegler S; Kumar P; Wester HJ; Beck R; McEwan AJ; Wiebe LI; Schwaiger M
    J Nucl Med; 2005 Jan; 46(1):106-13. PubMed ID: 15632040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and Bioevaluation of Novel [
    Yang X; Wang F; Zhu H; Yang Z; Chu T
    Mol Pharm; 2019 May; 16(5):2118-2128. PubMed ID: 30964298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
    Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
    Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal PET Imaging to Monitor Treatment Efficacy by Liposomal Irinotecan in Orthotopic Patient-Derived Pancreatic Tumor Models of High and Low Hypoxia.
    Ventura M; Bernards N; De Souza R; Fricke IB; Hendriks BS; Fitzgerald JB; Lee H; Klinz SG; Zheng J
    Mol Imaging Biol; 2020 Jun; 22(3):653-664. PubMed ID: 31482415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine.
    Beck R; Röper B; Carlsen JM; Huisman MC; Lebschi JA; Andratschke N; Picchio M; Souvatzoglou M; Machulla HJ; Piert M
    J Nucl Med; 2007 Jun; 48(6):973-80. PubMed ID: 17536108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring response to gefitinib in nude mouse tumor xenografts by (18)F-FDG microPET-CT: correlation between (18)F-FDG uptake and pathological response.
    Zhou LN; Wu N; Liang Y; Gao K; Li XY; Zhang LF
    World J Surg Oncol; 2015 Mar; 13():111. PubMed ID: 25888731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.